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In palliative cancer treatment, the choice between palliative chemotherapy and best supportive care may be difficult. In the decision-
making process, giving information as well as patients’ values and preferences become important issues. Patients, however, may have a
treatment preference before they even meet their medical oncologist. An insight into the patient’s decision-making process can
support clinicians having to inform their patients. Patients (n¼207) with metastatic cancer, aged 18 years or older, able to speak
Dutch, for whom palliative chemotherapy was a treatment option, were eligible for the study. We assessed the following before they
consulted their medical oncologist: (1) socio-demographic characteristics, (2) disease-related variables, (3) quality-of-life indices, (4)
attitudes and (5) preferences for treatment, information and participation in decision-making. The actual treatment decision, assessed
after it had been made, was the main study outcome. Of 207 eligible patients, 140 patients (68%) participated in the study. At
baseline, 68% preferred to undergo chemotherapy rather than wait watchfully. Eventually, 78% chose chemotherapy. Treatment
preference (odds ratio (OR)¼10.3, confidence interval (CI) 2.8–38.0) and a deferring style of decision-making (OR¼4.9, CI 1.4–
17.2) best predicted the actual treatment choice. Treatment preference (total explained variance¼38.2%) was predicted, in turn, by
patients’ striving for length of life (29.5%), less striving for quality of life (6.1%) and experienced control over the cause of disease
(2.6%). Patients’ actual treatment choice was most strongly predicted by their preconsultation treatment preference. Since treatment
preference is positively explained by striving for length of life, and negatively by striving for quality of life, it is questionable whether the
purpose of palliative treatment is made clear. This, paradoxically, emphasises the need for further attention to the process of
information giving and shared decision-making.
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Eventually, almost 50% of cancer patients will have metastatic
disease (Dutch Cancer Foundation, 1999). Still, making treatment
decisions in palliative cancer treatment is a complex task for
patients as well as physicians. This is particularly true because
there is no evident ‘best’ option. This paper reports a prospective
study on patients having to make a choice between palliative
chemotherapy and best supportive care. Palliative chemotherapy
aims at the alleviation of symptoms or postponing future
symptoms of the disease and thus maintaining or enhancing
quality of life. Survival gains, if present, are modest. For an
individual patient, it is uncertain whether symptom alleviation or
survival gain can be achieved while side effects are likely to occur.
Best supportive care is the alternative option and aims at
enhancing quality of life by the relief of symptoms once they
occur. At the same time, limited survival gain, even a few extra
months, may be important from the patient’s perspective.
Whether a patient with metastatic cancer should be treated with
palliative chemotherapy or choose best supportive care is therefore
not always evident. Clinically seen, individual patients may benefit
from palliative chemotherapy. However, contradicting evidence
can be found in the literature on the effects of chemotherapy on
the quality of life. There are studies in which chemotherapy
appears to enhance patients’ quality of life (Thatcher et al, 1997;
Stockler et al, 1998; Tannock, 1998; Geels et al, 2000; Doyle et al,
2001). Ramirez et al (1998) found that only 25% of the patients
benefited from chemotherapy in her study, and there are several
studies in which no improvement or even deterioration of quality
of life was reported (Quantin et al, 2000; van Andel et al, 2000;
Barras et al, 2001; Schiller et al, 2001). Values of patients thus
become more important. Knowledge of the factors upon which
patients’ preferences or the patients’ actual choice are based is
necessary in guiding the patient through the decision-making
process.
Four factors influencing cancer patients’ treatment choice have
been distinguished by Richards et al (1995): patients’ attitudes and
beliefs, doctors’ attitudes, the way information is presented and the
nature of the risk and benefit involved in the different treatment
options. Patients’ attitudes and beliefs are thought to be based on
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lprevious experience, family, friends, media and other health-care
professionals (Richards et al, 1995; Jansen et al, 2001). Doctors’
attitudes are influenced by what they think is the aim of the
therapy; relief of symptoms, extending life and giving hope (Maher
et al, 1992). Several studies have looked at the influence of the way
information is presented to patients (McQuellon et al, 1995; Yellen
and Cella, 1995; Flood et al, 1996; Mazur and Hickam, 1997;
O’Connor, 1998). It was found that the framing of information
affects patients’ choices (Siminoff and Fetting, 1991; McQuellon
et al, 1995; Flood et al, 1996; Mazur and Hickam, 1997; O’Connor,
1998). The nature of the risk and benefit of the different treatment
options can indeed influence the patient’s treatment choice, as
shown in several studies concerning early disease (Richards et al,
1995). However, the relative value attached to treatment options in
palliative care, such as chemotherapy and supportive care, is less
well documented (Richards et al, 1995).
In contrast to the lack of studies on treatment choice, several
studies have been performed on the nature and background of
treatment preference (Cassileth et al, 1980; McNeil et al, 1982;
Llewellyn-Thomas et al, 1995; Flood et al, 1996; Brundage et al,
1997; Mazur and Hickam, 1997; Lindley et al, 1998; Silvestri et al,
1998; Stalmeier and Bezembinder, 1999; Stiggelbout and de Haes,
2001). In the literature, the patient’s preference for treatment is
seen and used as an indication for their actual treatment choice.
However, patients’ actual treatment choice and their intended
choice or treatment preference are not necessarily the same, since
treatment preference is usually assessed in patients or subjects who
are not actually facing the choice investigated.
Several factors are found to affect treatment preference. Firstly,
framing influences treatment preferences, that is, whether out-
comes are presented in terms of survival or in terms of death, and
whether or not medical uncertainties are explicitly mentioned
(McQuellon et al, 1995; Flood et al, 1996; Mazur and Hickam, 1997;
O’Connor, 1998). Secondly, disease experience seems to be of
influence: patients are more willing than the general public or
medical staff to accept toxic treatment (Slevin et al, 1990; Degner
and Sloan, 1992; Brundage et al, 1997). Thirdly, various demo-
graphic variables such as age, living with others and having
children may also have an impact on treatment preferences of
patients (Kiebert et al, 1994; Unic et al, 1998).
It is generally assumed that patients form preferences and make
decisions after they have been informed by their physician.
Preferences for treatment are thus usually assessed after patients
have received information concerning their treatment options
(McNeil et al, 1982; Flood et al, 1996; O’Connor, 1998; Lindley et al,
1998; Silvestri et al, 1998). However, the patient, being a modern
consumer of health care, is not a tabula rasa. The notion that
medical professionals are the first to discuss certain topics and that
patients depend fully on their information and advice, is no longer
necessarily true. Patients have information from family, friends,
media or the Internet. Based on these sources of information, most
patients may already have an idea about chemotherapy and
whether they want it for themselves or not. To what extent these
preferences translate into a treatment decision is unknown.
To understand the decision-making process in palliative
chemotherapy, we investigated the actual treatment choice of
patients with metastatic cancer. Owing to its indicative value, we
prospectively studied their strength of preference for palliative
chemotherapy or best supportive care in cancer patients before
they consulted their medical oncologist. Finally, we investigated
whether this treatment preference, patient or disease character-
istics, quality of life, attitudes or preference for information and
participation in decision-making were predictive of the actual
treatment choice.
Our conceptual model is presented in Figure 1.
PATIENTS AND METHODS
This prospective study took place between June 1998 and April
2000. Patients with various types of metastatic cancer, aged above
18 years, able to understand and speak Dutch, referred because
palliative chemotherapy had become a treatment option were
eligible for the study. The patients were approached as soon as an
appointment with their medical oncologist was scheduled. After
informed consent was given, an appointment was made for an
interview prior to the first consultation with their medical
oncologist. After the decision concerning palliative chemotherapy
or best supportive care had been made, the treatment choice was
checked. To facilitate participation, the interview was held at the
patient’s home.
Medical oncologists (n¼37) from three academic and seven
nonacademic hospitals participated in the study. They completed a
disease-related checklist for each patient after they had seen the
patient during consultation. The oncologist informed the re-
searchers about the treatment decision as soon as it was made.
This was checked with the patient within 3 weeks. Ethical approval
was obtained from the ethics committee of each participating
hospital.
Measures
Dependent variables For ethical reasons, we did not want to
interfere with the expectations or knowledge of patients before the
consultation took place. Therefore, we first asked them in an open-
ended question as to what treatment they expected their physician
would propose in the upcoming consultation. Next, the strength of
preference for chemotherapy was assessed in those patients who
expected their medical oncologist to propose chemotherapy as one
of the options with a single question on a seven-point Likert scale
(‘strong aversion to chemotherapy’ to ‘strong preference for
chemotherapy’). If a patient did not mention chemotherapy, the
part of the questionnaire concerning chemotherapy was skipped.
Patients’ choices were assessed, as described, after the actual
decision was made.
Predictor variables The independent variables, that is (1) socio-
demographic patient characteristics, (2) disease-related variables,
(3) quality-of-life indices and (4) attitudes were assessed at
baseline (1, 3, 4) or obtained from the oncologist (2).
Demographic variables included gender, age, marital status,
having children and educational level. Disease-related variables
comprised type of cancer and performance status, the Karnofsky
index (Karnofsky and Burchenal, 1949)
Quality of life was measured with the Rotterdam Symptom
Checklist (RSCL) (de Haes et al, 1990). The RSCL is a validated,
cancer-specific questionnaire and covers physical distress (22
items, Cronbach’s a¼0.80 in the present study), psychological
distress (eight items, a¼0.89) and the daily activity level (eight
items, ADL; a¼0.86). The item scores range from 1 to 4. Sum
scores were transformed to the same scale. Low scores on the
physical and psychological distress scale reflect a better quality of
Explanatory variables  Intermediate variable  Outcome variable
-  Demographic
   characteristics
-  Disease-related
   variables
-  Quality-of-life
   variables 
-  Attitudes         
Preference for
chemotherapy  
Treatment 
choice
Figure 1 Conceptual model (explanatory variables, intermediate vari-
able and outcome variable).
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llife, whereas low scores on the activity level scale indicate a worse
quality of life.
Several attitudes were assessed. The Cancer Locus of Control
Scale (CLOC) covers the attitude of patients towards the origin and
the course of their illness (Pruyn et al, 1988; Watson et al, 1990). It
consists of three subscales: internal control over the disease
process (a¼0.74), internal control over the cause of the disease
(a¼0.64) and religious control (a¼0.88). Item scores range from
1 to 4, a higher score indicating a higher level of control.
The patient’s decision style was assessed with The Michigan
Assessment of Decision Style (MADS) (Pierce, 1993, 1995). The
MADS is developed for decision-making in early-stage breast
cancer, and validated. It was translated into Dutch for the current
study by two bilingual individuals, using a forward–backward
translation procedure. It covers: (1) avoidance (four items, e.g. ‘I
prefer not knowing the possibility that unexpected things could
happen to me’, a¼0.55); (2) deferring responsibility (three items,
e.g. ‘’I would follow the recommendations of my physician’,
a¼0.66); (3) information seeking (four items, e.g. ‘I would spend
as much time as I could gathering information’, a¼0.83); and (4)
deliberation (five items, e.g. ‘I would carefully consider the risks of
each option as I was making a choice’, a¼0.73). The scale scores
were linearly converted to a 0–100 scale, with higher scores
indicating a higher level of avoidance, deferring of responsibility,
information seeking and deliberation.
Patients’ attitudes towards striving for length (quantity) (four
items, a¼0.75) or quality of life (four items, a¼0.69) were
assessed by the ‘QQ-Questionnaire’ (QQQ) (Stiggelbout et al,
1996). High scores on the quantity or quality scale indicate the
importance of length and quality of life, respectively.
Preference for information was measured using a 10-point
rating scale, ranging from score 1 (wanting as little information as
possible) to score 10 (wanting all the information there is)
(Blanchard et al, 1988). Patients’ preference for participation in
decision-making was assessed on a five-point rating scale ranging
from giving the physician full responsibility for decision-making
(score 1), to the patient wanting to take this role (score 5)
(Sutherland et al, 1989; Degner and Sloan, 1992).
Statistical analyses
Univariate associations between baseline preference for treatment
and demographic characteristics, disease-related factors, quality of
life and attitudes were established with Pearson’s product moment
correlations and point biserial correlation coefficients.
Significant predictors of treatment preference (with P set at
o0.25) identified from the univariate analyses were then entered
into a multiple linear regression analysis, with a forward selection
strategy, using the F-statistic with P¼0.05 as the criterion level for
selection in the multivariate analyses.
Possible predictors of treatment choice were analysed with the
w
2 statistic and expressed in crude relative risk (RR) estimates with
their 95% confidence intervals (CI). Continuous variables were
dichotomised by using the median split method. For baseline
treatment preference, however, a content-related split was made
(either having or not having a preference for chemotherapy). Due
to skewness, the preference for information scale scores was
recoded as ‘do not prefer as many details as possible’ (1–9), and
‘prefer as many details as possible’ (10). Additionally, all variables
univariately associated with treatment choice (P-value set at
o0.25) were entered in a logistic regression model to assess their
independent prognostic value for treatment choice. Effect sizes
were expressed in odds ratios (ORs) (with their 95% CI).
Calibration of the regression model was assessed with the
Hosmer–Lemeshow goodness-of-fit test. In this test, a high P-
value indicates that the model is acceptable. All analyses were
performed in SPSS (version 10.0.7).
RESULTS
Patients
Of 242 patients, recruited over a 2-year period, 35 patients were
not eligible because they were treated with curative intent or were
not offered the choice of palliative chemotherapy. Of the remaining
207 patients, 140 patients were interviewed (68% response).
Reasons for not willing to participate at baseline were as follows:
Table 1 Patient characteristics (n¼140)
a
N%
Socio-demographic
Gender
Male 85 61
Female 55 39
Age (years)
26–50 27 19
51–60 40 29
61–70 45 32
71–82 28 20
Children
Yes 119 85
No 21 15
Education
Primary school 30 22
High school 81 58
College or higher 28 20
Disease-related
Type of cancer
Breast cancer 14 10
Head and neck cancer 22 16
Gastric-intestinal
cancer (sum)
68 49
Oesophagus 9 6
Stomach 7 5
Colon 28 20
Pancreatic 9 6
Rectum 14 10
Non-small-cell
lung cancer
96
Other 27 19
Performance status
100 53 39
90 48 35
80 23 17
70 9 7
60 3 2
Quality of life
Physical distress M¼1.50; s.d.¼0.34
Psychological distress M¼1.74; s.d.¼0.64
ADL activity level M¼3.70; s.d.¼0.52
Attitudes
Locus of control
Disease process M¼3.18; s.d.¼0.60
Cause of the disease M¼1.80; s.d.¼0.54
Religious M¼2.13; s.d.¼1.16
Decision-making style
Information seeking M¼2.66; s.d.¼0.93
Deliberation M¼3.98; s.d.¼0.56
Avoidance M¼2.43; s.d.¼0.65
Deferring M¼3.98; s.d.¼0.58
Striving for length of life M¼3.35; s.d.¼1.13
Striving for quality of life M¼3.74; s.d.¼0.99
Preference for information M¼8.91; s.d.¼1.99
Preference for participation M¼3.07; s.d.¼0.79
aDue to missing values, the numbers do not always add to 140. s.d.¼standard
deviation.
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lpoor physical condition (n¼39), reported psychological distress
(n¼2), time constraints (n¼10) or unspecified (n¼16). The
actual treatment decision could be confirmed by 131 patients.
Nonresponse was due to being too ill (n¼6) or death (n¼3).
Patient characteristics are presented in Table 1. More than half
of the sample was male (61%); the mean age was 60 years (s.d.
11.6).
Treatment preference and actual choice
Most patients (n¼114; 81%) expected that their medical
oncologist would propose chemotherapy. Subsequently their
preference for chemotherapy could be assessed. Patients who did
not answer that they expected the physician to propose
chemotherapy (N¼26) were older (Po0.01).
The distribution of the baseline treatment preference is
presented in Figure 2. Most patients (68%) favoured chemotherapy
at baseline. The majority of these had a very strong preference for
chemotherapy. Eventually 78% chose to undergo chemotherapy. In
Figure 2 the actual choice is shown, per treatment preference
category. The original treatment preference and the eventual
treatment choice turned out to be related. Almost all patients who
preferred chemotherapy before they visited their medical oncol-
ogist chose chemotherapy after they had discussed their treatment.
Approximately half of the patients (56%) who had no clear
treatment preference before they met with their oncologist chose
chemotherapy. Of those who had an aversion towards chemother-
apy (7%), almost all chose best supportive care, eventually.
Explaining treatment preference at baseline
In Table 2, the relation between preference for chemotherapy and
the explanatory variables is presented.
Younger patients had a stronger preference for chemotherapy.
Neither other demographic variables nor disease-related or
quality-of-life-related variables were significantly related to the
patients’ preference for palliative chemotherapy, although some
attitudes were. High levels of internal control concerning the
disease process, having a stronger deferring decision style, striving
for length of life and having a low preference for participating in
the decision-making were associated with a stronger preference for
chemotherapy. Striving for quality of life was negatively related to
the strength of preference for chemotherapy.
Multivariate analyses indicated that patients’ preferences for
chemotherapy were best explained by striving for length of life
(b¼0.38, partial R
2¼29.5%), whereas less striving for quality of
life added 6.1% (b¼ 0.29) to the explained variance. Feeling
internal control concerning the cause of the disease added an
additional percentage of 2.6% (b¼0.16).
Explaining treatment choice
In Table 3, the univariate relations between explanatory factors
and treatment choice are shown. None of the socio-demographic
variables was significantly related to the treatment chosen, nor
were disease-related variables and quality of life; however,
attitudes were. Having a deferring decision style, striving for more
length of life and less for quality, as well as having a strong
preference for palliative chemotherapy at baseline were all
significantly predictive of an eventual choice for palliative
chemotherapy.
0
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35
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45
1 Very strong preference
2 Strong preference
3 Preference
4 No preference
5 Aversion
6 Strong aversion
7 Very strong aversion
% choosing chemotherapy
% choosing best supportive care 
Figure 2 Preferences for either palliative chemotherapy or best
supportive care and the patients’ actual treatment choice (n¼1).
Table 2 Relation (univariate) between patient characteristics at baseline
and their strength of preference for palliative chemotherapy (n¼114)
Preference for chemotherapy
a
r
b P
Socio-demographic
Gender  0.09 0.32
Age (older)  0.20 0.04
Children
c 0.06 0.52
Education  0.05 0.63
Disease-related
Type of cancer
c
Breast 0.10 0.28
Head/neck 0.15 0.12
Gastric-intestinal
cancer (sum)
 0.10 0.28
Lung 0.04 0.67
Performance status 0.02 0.81
Quality of life
Physical distress 0.05 0.58
Activity level (ADL)
d  0.11 0.23
Psychological distress
e 0.11 0.24
Attitudes
Locus of control
Disease process
f 0.25 o0.01
Cause of the
disease
f
0.16 0.10
Decision style
Information seeking
g  0.01 0.95
Deliberation
g  0.05 0.63
Avoidance
g  0.03 0.76
Deferring
g 0.30 o0.001
Striving for length
of life
0.55 o0.001
Striving for quality
of life
 0.51 o0.001
Preference for
information
0.15 0.10
Preference for
participation
 0.18 0.06
aPositive signs indicate a stronger preference for chemotherapy.
bPMCCs.
cPoint
biserial correlation.
dHigher score less limited.
eHigher score more distress.
fHigh
scores indicate high control.
gHigh scores indicate a more active style.
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lTable 3 Relation between patient characteristics and preference for chemotherapy at baseline, and the patients’ actual treatment choice (n¼131)
a
Treatment choice (N)
Background factors Chemotherapy Best supportive care Crude RRb 95% CI P
Socio-demographic
Sex
Female 42 9
Male 60 20 1.10 0.92–1.31 0.32
Age (years)
461 46 15
p61 56 14 0.94 0.78–1.13 0.53
Children
Yes 87 25
No 15 4 0.98 0.76–1.27 0.90
Education
High 26 8
Low 75 21 0.98 0.79–1.21 0.84
Disease-related
Type of cancer
Breast cancer
Yes 12 1
No 90 28 1.21 1.00–1.46 0.19
Head/neck cancer
Yes 15 5
No 87 24 0.96 0.73–1.26 0.74
Gastric-intestinal cancer (sum)
Yes 47 16
No 55 13 0.92 0.77–1.11 0.39
Lung cancer
Yes 8 1
No 94 28 1.15 0.90–1.48 0.41
Performance status 53 21
p90 48 8 0.84 0.70–1.00 0.06
490
Quality of life
Physical distress
High (41.47) 49 12
Low (p1.46) 53 17 1.06 0.88–1.27 0.53
Activity level (ADL)
High (43.76) 62 15
Low (p3.75) 40 14 1.09 0.90–1.32 0.38
Psychological distress
High (41.51) 49 15
Low (X1.50) 53 14 0.97 0.81–1.16 0.73
Attitudes
Locus of control
Disease process
High control (41.5) 54 13
Low control (p1.5) 48 15 1.06 0.88–1.27 0.54
Cause of the disease
High control (43.37) 44 14
Low control (p3.37) 58 15 0.95 0.79–1.15 0.62
Decision-making style
Information seeking
High (X2.75) 50 17
Low (o2.75) 52 12 0.92 0.77–1.10 0.36
Deliberation
High (X4.0) 55 19
Low (o4.0) 47 10 0.90 0.75–1.08 0.27
Avoidance
High (X2.5) 55 18
Low (o2.5) 47 11 0.93 0.78–1.11 0.44
Deferring
High (X4.0) 41 3
Low (o4.0) 61 26 1.33 1.13–1.56 o0.01
Striving for length of life
Length more important (43.4) 5
Length less important (p3.4) 43 24 1.44 1.18–1.74 o0.001
Striving for quality of life
Quality more important (43.4) 45 22
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lFrom Table 4, presenting the multivariate analysis explaining
patients’ actual treatment choices, it appears that only ‘baseline
preference for chemotherapy’ and ‘a deferring decision style’
explain the eventual treatment choice. Patients with a strong
baseline preference for chemotherapy were substantially more
likely to choose chemotherapy (OR¼10.3). Patients who had a
deferring decision style were also more likely to start chemother-
apy (OR¼4.9). The Hosmer–Lemeshow goodness-of-fit statistic
(P¼0.73) indicated that the multiple regression model was well
calibrated.
DISCUSSION
The most remarkable finding in our study is, in our view, that the
patients’ preference for chemotherapy as assessed before they met
with their medical oncologist, most strongly predicted their
eventual treatment choice. Patients seem to make up their minds
about starting or forgoing palliative chemotherapy before they are
informed by their medical oncologist and, thus, outside the
consultation room. A conclusion therefore must be that what was
said during the consultation did not change much of the patient
preference and eventual choice.
Another striking finding is that the initial treatment preference
was strongly explained by striving for length of life. Oncological
consensus is that the expected outcomes of palliative chemother-
apy and best supportive care differ little in survival in most tumour
types (Glimelius et al, 2001; Ragnhammer et al, 2001). Still,
patients chose to be treated with chemotherapy, seemingly clinging
to the hope that this chemotherapy would extend their life
duration. They may thus not have received some basic information
or, alternatively, not have heard it. Alternatively, patients did not
want to hear this information or did not believe it and chose
palliative chemotherapy, being fully aware of its limited possibi-
lities regarding lengthening of life. Additionally, both a preference
for chemotherapy and choosing palliative chemotherapy were
negatively associated with striving for quality of life. Bearing in
mind the purpose of palliative chemotherapy, the enhancement or
maintenance of quality of life (Porzsolt, 1993; Porzsolt and
Tannock, 1993), one would expect striving for quality of life to
be positively associated with preference and choice for palliative
chemotherapy. Therefore, one can question whether the purpose of
palliative chemotherapy has been clearly explained to and is
understood by all patients.
Of the patients in our study, 68% had a preference for
chemotherapy, before they had received information from their
medical oncologist about treatment options; 78% of the patients
decided to undergo palliative chemotherapy eventually. In other
words, in absolute sense the impact of the consultation on the
treatment chosen is limited. The relationship between preference
for treatment and the actual treatment choice has not been
investigated thoroughly (Yellen and Cella, 1995; Jansen et al, 2001).
In retrospect, it is less surprising that the treatment preference at
baseline is so closely related to the actual treatment choice. For
patients and physicians, choosing an active treatment option, that
is, palliative chemotherapy, seems obvious. Best supportive care is
often perceived as ‘doing nothing’ (Charles et al, 1998). For
medical oncologists, the patient’s wish is an important determi-
nant of their own preference for treatment (Charles et al, 1998;
Koedoot et al, 2002). Moreover, they also prefer to ‘do something’,
that is, offering chemotherapy, rather than offering best supportive
care (de Haes and Koedoot, 2003). Thus, patients’ and oncologists’
treatment preferences seem to coincide, making a choice for
chemotherapy more likely.
Treatment choice was also predicted by having a deferring style
of decision-making. Patients having such decision-making style
were more likely to undergo chemotherapy than others. Since
medical oncologists, being experts in systemic treatment, want to
offer a treatment, and spend more time explaining chemotherapy
than explaining best supportive care, they may convey the
suggestion that they prefer palliative chemotherapy (Koedoot
et al, 1996). It is then likely that a deferrer, who would like to lean
on the oncologist’s advice, is inclined to choose chemotherapy.
The absence of an association between a deferring decision-
making style and baseline preference for chemotherapy is not
surprising, since at baseline deferrers are not yet aware of the
oncologist’s preference. They have not had an opportunity to defer
the decision to their oncologist yet.
Some limitations of our study have to be mentioned. Firstly,
there is most likely a referral bias. Patients, who visit a medical
oncologist, often have a positive attitude towards treatment
already. Indeed, two-thirds of our patients preferred to be treated
with palliative chemotherapy before the consultation. Secondly, for
Quality less important (p3.4) 57 7 0.75 0.62–0.91 o0.01
Preference for information
Strong (10) 69 16
Weak (0–9) 33 13 1.13 0.92–1.39 0.21
Preference for participation
Strong (3–5) 89 27
Weak (1, 2) 13 2 0.89 0.71–1.11 0.38
Preference for chemotherapy
Preference (1–3) 67 6
No preference (4–7) 15 18 2.02 1.38–2.95 o0.001
aDue to missing values, the numbers do not always add to 131.
bRR41 indicates a stronger likelihood to choose chemotherapy. RR¼relative risk; CI¼confidence interval.
Table 3 Continued
Treatment choice (N)
Background factors Chemotherapy Best supportive care Crude RRb 95% CI P
Table 4 Factors
a explaining treatment choice (n¼131)
ORb 95% CI P
Performance status 2.5 0.64–7.55 0.21
Deferring decision style 4.9 1.40–17.18 0.01
Striving for length of life 1.7 0.43–6.96 0.44
Striving for quality of life 1.1 0.29–4.16 0.89
Preference for information 2.5 0.74–8.20 0.14
Preference for chemotherapy 10.3 2.80–37.96 o0.001
aDue to cells with zero respondents, having breast cancer was left out of the Logistic
regression analysis.
bMultivariate logistic regression analysis. Hosmer and Lemeshow
test: P¼0.73. OR¼odds ratio; CI¼confidence interval.
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lethical reasons, only patients who mentioned that they expect their
physician to offer them palliative chemotherapy were included in
the analyses. In doing so, we could have created a selection bias. Patients
who did not expect their oncologist to offer them chemotherapy were
older than those who expected their oncologist to offer chemotherapy
(t¼ 2.51, df¼138, P¼0.01). Still, age appeared to have no influence
on the actual treatment choice. Therefore we conclude that no important
selection bias is at stake. Thirdly, the content of the information given by
the referring specialists is unknown. Therefore, it would be of interest to
look at patients’ preferences even before they are referred to a medical
oncologist.
In conclusion, our results suggest that physicians could take
these preconsultation ideas and preferences into account when
providing information to patients. The information-giving process
should then address the limited survival benefit of palliative
chemotherapy and the possibility of best supportive care. Explicit
attention may also have to be given to the ‘natural’ inclination of
both physician and patient to ‘do something’, as it may be
questioned whether the modest survival gain, in palliative
chemotherapy, is to be considered worthwhile. Moreover, treating
with palliative chemotherapy may be less than good quality-of-life
care (Singer et al, 1999). Thus, the need for open physician–
patient communication and shared decision-making with regard to
treatment in this phase of the disease is stressed again. Finally, it
might be necessary to discuss explicitly the attitudes of patients
towards chemotherapy during the consultation in order to trace
possible misconceptions. Our findings, thus, point to the need for
a model of shared decision-making, in which different treatment
options are explained, patients’ attitudes and beliefs are investi-
gated and the actual treatment choice is the outcome of a joint
decision-making process (Charles et al, 1999). Especially because
the available treatment options are equivalent in palliative
treatment, this concept deserves extensive attention when propos-
ing palliative chemotherapy or best supportive care.
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